Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Tenalisib (RP6530)（一种双重 PI3K δ/γ 抑制剂）治疗复发/难治性 T 细胞淋巴瘤患者的 I/Ib 期研究
期刊:Cancers
影响因子:4.4
doi:10.3390/cancers12082293
Huen, Auris; Haverkos, Bradley M; Zain, Jasmine; Radhakrishnan, Ramchandren; Lechowicz, Mary Jo; Devata, Sumana; Korman, Neil J; Pinter-Brown, Lauren; Oki, Yasuhiro; Barde, Prajak J; Nair, Ajit; Routhu, Kasi Viswanath; Viswanadha, Srikant; Vakkalanka, Swaroop; Iyer, Swaminathan P
